TransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

TransMedics Group, Inc. (NASDAQ:TMDX) has been assigned a consensus rating of “Moderate Buy” from the ten brokerages that are currently covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $144.25.

Several brokerages recently commented on TMDX. Morgan Stanley raised their target price on TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of TransMedics Group in a report on Wednesday, October 8th. Jefferies Financial Group assumed coverage on shares of TransMedics Group in a research report on Monday, October 13th. They set a “buy” rating and a $145.00 target price on the stock. Wall Street Zen raised shares of TransMedics Group from a “hold” rating to a “buy” rating in a research report on Sunday, December 28th. Finally, Evercore ISI initiated coverage on shares of TransMedics Group in a research note on Tuesday, September 16th. They set an “outperform” rating and a $155.00 price target for the company.

TransMedics Group Trading Up 0.9%

NASDAQ:TMDX opened at $122.69 on Friday. The stock has a market cap of $4.19 billion, a PE ratio of 49.67 and a beta of 2.03. TransMedics Group has a fifty-two week low of $55.00 and a fifty-two week high of $156.00. The company has a debt-to-equity ratio of 1.43, a current ratio of 7.69 and a quick ratio of 7.13. The stock’s 50-day moving average is $128.91 and its two-hundred day moving average is $122.05.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Wednesday, October 29th. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.29. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The firm had revenue of $143.82 million for the quarter, compared to analyst estimates of $145.33 million. During the same quarter last year, the firm earned $0.12 earnings per share. The company’s revenue for the quarter was up 32.2% on a year-over-year basis. As a group, equities research analysts forecast that TransMedics Group will post 1 earnings per share for the current fiscal year.

Insider Buying and Selling

In other TransMedics Group news, insider Anil P. Ranganath sold 3,000 shares of the business’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $145.22, for a total value of $435,660.00. Following the transaction, the insider directly owned 13,955 shares in the company, valued at $2,026,545.10. The trade was a 17.69% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director David Weill sold 5,000 shares of the business’s stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $138.64, for a total transaction of $693,200.00. Following the completion of the transaction, the director directly owned 12,134 shares of the company’s stock, valued at approximately $1,682,257.76. This represents a 29.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 13,062 shares of company stock valued at $1,797,634 in the last ninety days. Insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On TransMedics Group

Hedge funds and other institutional investors have recently bought and sold shares of the business. Opal Wealth Advisors LLC acquired a new position in shares of TransMedics Group in the 2nd quarter valued at $26,000. Whittier Trust Co. of Nevada Inc. increased its holdings in TransMedics Group by 981.0% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock valued at $26,000 after purchasing an additional 206 shares during the last quarter. Salomon & Ludwin LLC acquired a new position in TransMedics Group in the third quarter valued at about $28,000. Harvest Fund Management Co. Ltd bought a new position in TransMedics Group during the third quarter worth about $29,000. Finally, Allworth Financial LP boosted its holdings in TransMedics Group by 74.3% during the third quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after buying an additional 113 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.